Active, not recruitingPhase 2NCT04942210
Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA
Studying Yellow fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Principal Investigator
- Clinical Sciences & OperationsSanofi Pasteur, a Sanofi Company
- Intervention
- Yellow fever vaccine (produced on serum-free Vero cells)(biological)
- Enrollment
- 568 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2021 – 2027
Study locations (11)
- Emory University Decatur- Site Number : 8400005, Decatur, Georgia, United States
- Velocity Clinical Research- New Orleans Site Number : 8400008, New Orleans, Louisiana, United States
- Johns Hopkins Bloomberg School of Public Health (JHSPH)- Site Number : 8400004, Baltimore, Maryland, United States
- Harvard University Medical School- Site Number : 8400002, Boston, Massachusetts, United States
- Saint Louis University- Site Number : 8400003, St Louis, Missouri, United States
- Meridian Clinical Research- Site Number : 8400009, Omaha, Nebraska, United States
- SUNY Upstate Medical University Global Health Institute Site Number : 8400006, East Syracuse, New York, United States
- New York University Langone Medical Center Site Number : 8400013, New York, New York, United States
- Rochester Clinical Research, Inc.- Site Number : 8400010, Rochester, New York, United States
- Velocity Clinical Research - Providence Site Number : 8400015, East Greenwich, Rhode Island, United States
- J Lewis Research Inc- Site Number : 8400012, Salt Lake City, Utah, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04942210 on ClinicalTrials.govOther trials for Yellow fever
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06694766VAC-SIP-YF (Vaccination- Safety & Immunogenicity During Pregnancy- Yellow Fever)Institut Pasteur
- RECRUITINGNANCT06718127Description of the Immune Response to Yellow Fever VaccinationInstitut Pasteur
- RECRUITINGPHASE1, PHASE2NCT05859490Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D VaccinationOregon Health and Science University
- ACTIVE NOT RECRUITINGNANCT05644145Immunogenicity of Yellow Fever Vaccine in a Pediatric Population Vaccinated at 12-23 Months of Age in ArgentinaMinistry of Public Health, Argentina
- ACTIVE NOT RECRUITINGPHASE2NCT05011123Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and AsiaSanofi Pasteur, a Sanofi Company
- ACTIVE NOT RECRUITINGPHASE4NCT04083430Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D VaccinationUniversity of Aarhus
- RECRUITINGPHASE4NCT03132311Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected IndividualsOswaldo Cruz Foundation
- ACTIVE NOT RECRUITINGPHASE4NCT02555072Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)